Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling studyResearch in context

• Egile Nagusiak: Caroline Cândida Carvalho de Oliveira (Egilea), Leandro Barile Agati (Egilea), Camilla Moreira Ribeiro (Egilea), Valéria Cristina Resende Aguiar (Egilea), Roberto Augusto Caffaro (Egilea), Marisa da Silva Santos (Egilea), Ricardo Ribeiro Alves Fernandes (Egilea), Carlos Alberto da Silva Magliano (Egilea), Alfonso Tafur (Egilea), Alex C. Spyropoulos (Egilea), Renato Delascio Lopes (Egilea), Jawed Fareed (Egilea), Eduardo Ramacciotti (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2023-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Summary: Background: In patients at high risk of thromboembolism who were discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days significantly improved clinical outcomes, reducing thrombotic events compared with no post-discharge anticoagulation....